Ohmx

Executive Summary

Ohmx is a Belgian biotechnology company founded in 2019 that specializes in multi-omics sequencing and bioinformatics services, leveraging Oxford Nanopore long-read sequencing technology. The company positions itself as a scientific partner for research and clinical diagnostics, offering end-to-end solutions from sample preparation to data analysis. By focusing on long-read sequencing, Ohmx addresses key limitations of short-read technologies, such as resolving complex genomic regions, detecting structural variants, and characterizing epigenetic modifications. This capability is increasingly valuable in applications like cancer genomics, rare disease diagnosis, and infectious disease surveillance. Based in Leuven, Belgium, Ohmx operates in the rapidly growing multi-omics market, which is expected to expand as precision medicine advances. Although the company is private and has not disclosed funding or valuation, its specialized service model and technological focus may position it for partnerships with research institutions, pharmaceutical companies, and diagnostic laboratories. However, competition from established sequencing service providers and the need for continuous innovation pose challenges.

Upcoming Catalysts (preview)

• Q2 2026Announcement of a major collaboration with a pharmaceutical or academic institution60% success
• Q4 2026Launch of a new bioinformatics analysis platform or upgrade50% success
• Q1 2027Expansion into clinical diagnostics with a CE-IVD marked test30% success